Last reviewed · How we verify
NCT06644443
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Phase 1, PHASE2 trial testing BCMA-GPRC5D CAR-T cells in Multiple Myeloma in Relapse in 10 participants. Currently enrolling.
14 July 2025
Quick facts
| Lead sponsor | Shenzhen University General Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 15 July 2023 |
| Primary completion | 14 July 2025 |
| Estimated completion | 14 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- BCMA-GPRC5D CAR-T cells — full drug profile →
Conditions studied
- Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
Sponsor
Shenzhen University General Hospital
Who can join
Adults 18 to 75, any sex, with Multiple Myeloma in Relapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At present, MM is still an incurable disease in general, and the vast majority of patients will eventually face disease recurrence or progression. Although CAR-T therapy targeting BCMA has shown advantages in the efficacy and safety of MM, for MM patients with BCMA negative or BCMA low expression, they still relapse after receiving targeted BCMA CAR T-cell therapy, and there is a problem of target escape. The specific high expression of GPRC5D in multiple myeloma cells makes it possible to combine BCMA and GPRC5D in the treatment of MM. This study aims to investigate the safety and efficacy of BCMA-GPRC5D CAR-T therapy in the treatment of relapsed or refractory MM.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108 -
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma.
Yan S, Ming X, Zheng R, Zhu X, et al · · 2025 · cited 3× · PMID 40095426 · DOI 10.1002/cam4.70764
Verify or expand the search:
- PubMed search for NCT06644443
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma in Relapse
Currently open trials in the same condition.
- NCT07096778 — Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06822972 — HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · Phase 2 · recruiting
- NCT07032129 — Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07248176 — Universal CAR-T Cell Therapy for MM · NA · recruiting
- NCT06846905 — Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma. · recruiting
Other Shenzhen University General Hospital trials
Trials by the same sponsor.
- NCT07508605 — Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT07399769 — Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
- NCT07097207 — Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT05620693 — Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma · NA · recruiting
- NCT05620706 — Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06644443 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen University General Hospital
- Last refreshed: 16 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06644443.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing